Physician profile
Eugenio M Capitle
NPI 1568411650
$756.18
in general payments reported to CMS, 2019-2025
12 companies · $26.90 in 2025
The $26.90 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $80.61 · 2021: $28.92 · 2022: $30.45 · 2023: $328 · 2024: $14.34 · 2025: $26.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $233.64 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $134.13 | 2023 | Saphnelo |
| Ucb, INC. | $130.01 | 2023 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Abbvie INC. | $90.74 | 2020-2023 | Rinvoq |
| Genzyme Corporation | $26.90 | 2025 | |
| Amgen INC. | $14.34 | 2024 | Krystexxa |
| Horizon Therapeutics Plc | $13.72 | 2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $12.71 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugenio Capitle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.